EP Patent

EP3508477A1 — C5ar antagonists

Assigned to Chemocentryx Inc · Expires 2019-07-10 · 7y expired

What this patent protects

A process for preparing a compound of formula (ii),comprising(a) treating a compound of formula (i) with Hand a platinum oxide catalyst under reducing conditions; and(b) subjecting the product of step (a) to resolution with di-toluoyl-L-tartaric acid to provide compound (ii) in a…

USPTO Abstract

A process for preparing a compound of formula (ii),comprising(a) treating a compound of formula (i) with Hand a platinum oxide catalyst under reducing conditions; and(b) subjecting the product of step (a) to resolution with di-toluoyl-L-tartaric acid to provide compound (ii) in about 97% enantiomeric excess.

Drugs covered by this patent

Patent Metadata

Patent number
EP3508477A1
Jurisdiction
EP
Classification
—
Expires
2019-07-10
Drug substance claim
No
Drug product claim
No
Assignee
Chemocentryx Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.